Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of IV Zanamivir in Healthy Chinese Adults
NCT02377401Phase 1Completed
- Sponsor
- GSK
- Start
- Apr 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zanamivir in influenza (2 arms), sponsored by GSK. Primary endpoints: Composite of PK parameters of zanamivir following single dose administration at Day 1 and Composite of PK parameters of zanamivir following repeat dose administration at Day 8. Started Apr 2015; status: completed.
02
Drugs
zanamivir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02377401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02377401.